Avanir Drug Nuedexta Is First Treatment for Pseudobulbar Affect

The FDA has approved Avanir Pharmaceuticals’ Nuedexta, formerly Zenvia, as the first treatment approved in the U.S. for pseudobulbar affect (PBA). Avanir expects to launch Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) during the first quarter of 2011, CEO Keith Katkin said. PBA is characterized by involuntary, sudden and frequent laughing or crying. The condition is often seen in patients with underlying neurological disorders, such as stroke, multiple sclerosis, amyotrophic lateral sclerosis and traumatic brain injuries.
Drug Industry Daily